Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Clair Obscur: Expedition 33 is full of twists, turns, and world-changing events even before reaching the final act. So, it trusts that you’ve been paying full attention well before the final battle.